MediciNova Inc. (MNOV)
NASDAQ: MNOV
· Real-Time Price · USD
1.51
-0.01 (-0.66%)
At close: May 01, 2025, 3:59 PM
1.47
-2.65%
After-hours: May 01, 2025, 04:05 PM EDT
-0.66% (1D)
| Bid | 1.44 |
| Market Cap | 74.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.86B |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -6.57 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 1,641 |
| Avg. Volume (20D) | 15,891 |
| Open | 1.52 |
| Previous Close | 1.52 |
| Day's Range | 1.50 - 1.52 |
| 52-Week Range | 1.12 - 2.55 |
| Beta | 0.75 |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced periphera...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2006
Employees 13
Stock Exchange NASDAQ
Ticker Symbol MNOV
Website https://www.medicinova.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MNOV stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 496.03% from the latest price.
Stock Forecasts5 months ago
+14.98%
MediciNova shares are trading higher after D. Bora...
Unlock content with
Pro Subscription
5 months ago
+49.02%
MediciNova shares are trading higher after the company announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled.
